Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses advances in the treatment of advanced systemic mastocytosis (AdvSM), highlighting the impact of targeted KIT inhibitors on treatment outcomes. Prof. DeAngelo reviews findings from the EXPLORER (NCT02561988) and PATHFINDER (NCT03580655) trials of avapritinib, alongside emerging data from the APEX trial (NCT04996875) of bezuclastinib, exploring treatment responses, survival outcomes, and the challenges of managing associated hematologic neoplasms. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.